Northerner
Admin (Retired)
- Relationship to Diabetes
- Type 1
An improved version of Sanofi's blockbuster insulin Lantus is better than the older drug at controlling blood sugar lows at night, a common side effect in diabetics treated with insulin, according two late-stage tests published on Saturday.
The results for the next-generation treatment, known as U300, could strengthen Sanofi's position as it defends its no. 2 spot in the $43 billion diabetes market from rival drugs.
Lantus, a synthetic insulin developed in the 1990s, is currently Sanofi's top-selling product. Last year it grew almost 20 percent to generate 5 billion euros ($6.6 billion) in sales - but is set to lose patent protection in 2015.
http://uk.reuters.com/article/2013/06/22/us-sanofi-lantus-idUKBRE95L08R20130622
Hmm...patent about to expire, so let's bring out something we claim to be better...🙄
The results for the next-generation treatment, known as U300, could strengthen Sanofi's position as it defends its no. 2 spot in the $43 billion diabetes market from rival drugs.
Lantus, a synthetic insulin developed in the 1990s, is currently Sanofi's top-selling product. Last year it grew almost 20 percent to generate 5 billion euros ($6.6 billion) in sales - but is set to lose patent protection in 2015.
http://uk.reuters.com/article/2013/06/22/us-sanofi-lantus-idUKBRE95L08R20130622
Hmm...patent about to expire, so let's bring out something we claim to be better...🙄
